Status:
UNKNOWN
Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Gastric Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Background: It is shown that TS-1 as adjuvant chemotherapy after D2 resection in patients with gastric cancer can improve DFS and OS in one Japanese Trial. And TS-1 has become one of the standard ther...
Eligibility Criteria
Inclusion
- informed consensus of patients
- be able to receive oral administration
- from 18 to 70 years old
- be proven to be primary adenocarcinoma of gastric cancer and staged II or III by pathological evidences
- without other chemotherapy and/or radiation against to the disease
- normal function of other organs including heart,liver ,kidney and so on
- Eastern Cooperative Oncology Group performance status:0\~2
Exclusion
- history of other malignancy
- allergic reaction to S-1 or oxaliplatin
- be enrolling in other clinical trials
- abnormal GI tract function
- dysfunction of other organs
- female in pregnancy or lactation,or refuse to receive Contraception measures during chemotherapy
- other situation to be judged not adaptive to the study by investigators
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
724 Patients enrolled
Trial Details
Trial ID
NCT01795027
Start Date
September 1 2011
End Date
June 1 2018
Last Update
October 25 2016
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
the central hospital of Chaozhou
Chaozhou, Guangdong, China
2
the 1st people's hospital of Foshan
Foshan, Guangdong, China
3
cancer center of Guangzhou medical college
Guangzhou, Guangdong, China
4
cancer center of Sun yat-sen University
Guangzhou, Guangdong, China